Vivid Genomics, Inc.

-- Vivid Genomics is addressing a $50 billion market opportunity with precision medicine for dementia, with ramp to become a $1 billion company

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Diego, CA, USA
  • Currency USD
  • Founded January 2017
  • Employees 3
  • Incorporation Type C-corp
  • Website vividgenomics.com

Company Summary

-- Vivid Genomics is addressing a $50 billion market opportunity with
precision medicine for dementia, with ramp to become a $1 billion company
-- We use our proprietary, machine learning analytical platform to develop
non-invasive genetic tests; our first tests improve clinical trials in Alzheimer’s disease and other dementias, increasing the chance of successful trials and
the first disease-modifying drug approval in Alzheimer’s

Team

  • Katie M Breitenbach
    Finance/CFO/VP Finance

    Katie is an Internal Operator with financial acumen and tenure at Global tech firms. Trained accountant, controller, treasurer, and banker with continuous promotion, and business partners with key stakeholders. Postings at HQ and satellite offices (SiliconValley, London, NewYorkCity, Vienna, BuenosAires, Trinidad, MexicoCity).
    Email: katiebfinance@gmail.com

  • Julie Collens
    CEO

    Biotech professional with demonstrated success in the genomics industry and in sell-side equity analysis. Experience in genomics, molecular diagnostics, and life science tools. Strong marketing and strategic experience identifying and evaluating opportunities in new potential markets and devising and executing approaches for accelerating growth in novel genomic applications. PhD in evolutionary biology and population genetics

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free